Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
Date:7/10/2008

-- Top-Line Data Expected in the Third Quarter --

SAN FRANCISCO, July 10 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised carotid plaque tissue will be analyzed to determine VIA-2291's effect on inflammation, and the company remains on track to report top-line data in the third quarter.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

"Analyzing the carotid plaque collected in the CEA trial is a novel approach to aid investigators in the evaluation of VIA-2291's potential impact on inflammation," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "Our Phase 2 program, which includes this trial as well as two others, is designed to provide proof-of-concept evidence supporting the potential effectiveness of VIA-2291 and its further development."

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients in the study are treate
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. Isis Pharmaceuticals Conference Call Notice
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
9. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... legislators seek ways to reduce Medicaid spending, they should start ... fee-for-service model to the more efficient model used in some ... study finds that the program could save $473 million ... benefits more like those in Medicare and commercial plans. Governors ...
... Remedi SeniorCare®, which is among the nation,s ... care (LTC) pharmacy industry with the Paxit™ med-pass ... enabled by fully automated centralized proprietary dispensing technology. ... in Maryland and the Washington, D.C. area, where ...
Cached Medicine Technology:Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 2Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 3Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration 4
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a reliable source ... Mountain View, CA. Over the years Luke Bryan has been ... only does he do well at award shows, but each summer, ... most anticipated tours of the genre and this summer is more ... can compare to the popularity and success that is currently entitled ...
(Date:7/11/2014)... July 11, 2014 Last month Watkins ... Jim Siddons joins the agency as a specialist in ... 1994 with a Bachelor’s Degree in Business Administration from ... experience and will manage everything from performance and payment ... to the specialized needs for those in the asphalt ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... a history of hazardous or binge drinking reduced their ... mobile phone text messages following a visit to the ... in Annals of Emergency Medicine (" A ... Patients: A Randomized Clinical Trial "). , "Each day ... to 24 visit ERs and up to half have ...
Breaking Medicine News(10 mins):Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:Text message medicine: Texts from the ER can reduce binge drinking 2
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- When people ... anemia drugs, the level of hemoglobin cells in their blood ... if those levels don,t increase by much, these "poor responders" ... Reporting in the Sept. 16 issue of the ...
... The number of times our cells can divide is dictated ... chromosomes. Understanding how telomeres keep our chromosomes and by ... scientific focus in the fields of both aging and cancer. ... detailed report on the structure and function of a crucial ...
... Cancer Center at the University of California, San Diego ... by the American College of Radiology (ACR). ... standard and this prestigious certificate recognizes our extraordinary effort," ... at Moores UCSD Cancer Center. "ACR leads the way ...
... COLUMBIA, Mo. Studies show that nearly half ... Confusing medical directions, such as dosage and timing ... including health setbacks, inappropriate hospital admissions and, sometimes, ... School of Health Professions are examining what health ...
... HealthDay Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Fresh ... a new study shows that men who have a low prostate-specific ... Conversely, men with a high PSA reading -- 2 nanograms ... an increased risk of developing the disease, the researchers added. ...
... heart disease are more likely to suffer heart-focused ... sensations if their parents were overprotective during ... Orion Health Services in Vancouver, and colleagues from ... Canada, suggest that health care professionals could encourage ...
Cached Medicine News:Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3Health News:Protein clamps tight to telomeres to help prevent aging...and support cancer 2Health News:Protein clamps tight to telomeres to help prevent aging...and support cancer 3Health News:What can health-care facilities do to help patients better understand medical information 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 3Health News:Overprotective parents may impact heart anxiety in adults with congenital heart conditions 2
Adson bipolar forceps, 12 cm, straight....
Straight, blunt and pointed tips....
Angulated, blunt and pointed tips....
Blunt, 20 cm long....
Medicine Products: